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Abstract 
AIM: To evaluate copeptin as an early marker of atherosclerosis in adolescent type 1 diabetics. 
METHODS: Sixty-two type 1 diabetic patients and 50 healthy volunteers were enrolled in the study. Serum 
copeptin, glycosylated haemoglobin (HbA1c), lipid profile, oxidised low-density lipoprotein (OxLDL), urinary 
albumin/creatinine ratio, carotid intimal medial thickness (cIMT), aortic intimal medial thickness (aIMT) and 
resistivity index were assessed for all participants in the study. 
RESULTS: HbA1c, albumin/creatinine ratio, lipid profile, OxlDL, copeptin, cIMT and aIMT were significantly higher 
in diabetic patients. Copeptin was higher in patients with positive cIMT and aIMT. Copeptin correlated with cIMT 
and aIMT. Stepwise multiple regression analysis found that copeptin correlated with aIMT. ROC curve showed 
that copeptin had 100 % specificity with aIMT and cIMT and 95.2 and 60,7 sensitivity with aIMT and cIMT 
respectively. 
CONCLUSION: Copeptin can be used as a marker for early detection of atherosclerosis of type 1 diabetic 
patients. 
 
 
 
 
Introduction 
 
Diabetic nephropathy (DN) and cardiac 
complication being considered the most important 
factor for morbidity and mortality in type 1 diabetes 
(T1D) [1], [2]. Early detection of the coronary artery 
plaque by using Coronary artery calcification (CAC) is 
an indication of endpoint coronary artery disease 
(CAD) [2]. 
As Arginine vasopressin (AVP) is small in size 
and had a short half-life, it can not be easily measured 
[3]. AVP is essential for renal and cardiovascular 
function as it regulates the volume status. Although 
Copeptin and AVP are derived from the same 
precursor molecule, copeptin is a more stable peptide 
and used for evaluation of fluid and osmosis status in 
various diseases [3], [4]. 
Type 1 diabetic patients had higher AVP and 
exaggerated response to AVP concentrations [5], [6], 
which stimulate V1a receptors leading to diabetic 
cardiovascular complications. Although the 
relationship between copeptin, CAD and DN have 
been studied in adults with type 2 diabetes (T2D) [7], 
[8], yet from our knowledge, very minimal studies 
were done on type 1 diabetic patients. 
We aimed to study the association between 
copeptin and atherosclerosis and diabetic 
nephropathy. 
 
 
Patients and Methods 
 
This cross-sectional study was done on 62 
type of 1 diabetic patient and 50 healthy volunteers. 
The diabetic patients were selected from the 
endocrine clinic, Medical Center of Excellence, 
National Research Centre and the controls among 
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healthy children attending the Medical centre of 
Excellence with their relatives. The ethical committee 
approval from National Research Centre, Registration 
number 19101 was taken. Also, written consent was 
received from diabetics or their parents and controls. 
Diabetic patients (age > 14 and < 19 yrs) and 
duration of diabetes more than 5 years were selected. 
On the other hand, people with diabetes with acute 
diabetic complications, CVD, taking metformin or 
multivitamins or Smokers were excluded from the 
study. Demographic data of diabetic patients was 
taken. General, cardiac, chest and neurological 
examination were done for all diabetics and controls. 
Blood pressure was assessed for all diabetics and 
controls. It was measured three times after 5-minute 
rest in the sitting position by using automatic 
manometer (Omron M4 Plus, Omron Health care 
Europe, Hoof drop, and Holland). The mean value of 
the second and the third measurement was 
calculated. 
Weight, height, waist circumference (WC), 
and hip circumference (HC) were assessed for 
diabetics and controls. Weight (by Seca Scale 
Standing Balance) and height (by Holtain Portable 
anthropometer, Holtain, Ltd, Crymmych, Wales, U.K) 
were measured. Body mass index, waist/hip ratio and 
waist/height ratio (cm/cm) were calculated [9], [10]. 
After 12 hr fasting, venous blood was 
collected for assessment of lipid profile [11]. Low-
density lipoprotein (LDL) cholesterol was calculated 
using the Friedewald equation. Triglycerides (Tg) was 
measured in a Techno Con AutoAnalyzer II, 
Tarrytown, NY, USA. 
The mean value of glycosylated haemoglobin 
(HbA1c) of one year was recorded. Measurement of 
HbA1c every 3 was taken from files of patients. 
Screening for microalbuminuria was assessed 
in fresh morning urine samples by measuring 
albumin/creatinine ratio. Microalbuminuria was 
measured 3 times (separated every 2 months), and it 
was considered positive if 2 from 3 samples were 
positive. If one sample was positive urine analysis 
was done to exclude urinary tract infection. Copeptin 
and OxLDL were measured by the ELISA method 
(quantitative sandwich enzyme-linked immunosorbent 
assay technique). 
Assessment of Carotid intima-media 
thickness (cIMT) was done by using General Electric 
medical ultrasonographic machine model: Vivid 7 Pro, 
GE Vingmed ultrasound AS-Nl90, Horton-Norway 
equipped with 7.5–10 MHz linear-array transducer) 
[12]. 
 
Measurement of the aortic intimal medial 
thickness (aIMT) 
The transducer (7.5 MHz) was put in the 
upper abdomen for evaluation of abdominal aorta and 
aortic bifurcation. The aortic intima-media complex 
was assessed (10 MHz linear array transducer). For 
the assessment of aIMT, the image was focused on 
the far wall (dorsal arterial wall of the most distal 15 
mm of the abdominal aorta), and gain settings were 
used to optimise image quality [13]. The average of 3 
measurements of each patient was taken for 
evaluation of aIMT. 
Renal colour duplex scan by Toshiba, Xario 
ultrasound machine (3-6 MHz transducer) was done in 
Rt and Lt renal arteries for measurement of the peak 
systolic velocities and excluded renal artery stenosis 
in all patients by assessment of different segments 
starting from their origins to renal hila. Right, and left 
resistivity indices in segmental, interlobar and arcuate 
arteries were also measured [14]. 
 
Statistical Analysis 
Statistical Package for Social Science (SPSS) 
program version 20.0 (Chicago, Illinois, USA) was 
used. T-test for quantitative variables was done. We 
evaluate the correlation between copeptin with 
demographics, laboratory data, anthropometric data, 
and image study of diabetic patients. Pearson's 
correlation, followed by stepwise multiple regression 
analysis, were also done. Receiver Operating 
Characteristic curve (ROC curve) was used for 
detecting sensitivity and specificity of copeptin with 
cIMT and aIMT. Stepwise multiple regression analysis 
of copeptin about demographics, anthropometric data, 
laboratory data and image study in type 1 diabetic 
patients 
 
 
Results 
 
Glycosylated haemoglobin, albumin/ 
creatinine ratio, lipid profile OxLDL, copeptin, cIMT 
and aIMT were significantly higher in people with 
diabetes (Table 1). 
Table 1: Comparison between demographics, laboratory data, 
anthropometric and image study of diabetic patients and 
controls 
Variables 
Patients Controls 
P-value 
Mean SD Mean SD 
Age of diabetic patients (yrs) 17.99 2.59 17.50 2.67 0.6 
Systolic blood pressure (mmHg) 118.45 13.33 123.75 10.61 0.30 
Diastolic blood pressure (mmHg) 76.55 10.06 80.00 10.69 0.40 
Midarm circumfrence (mm) 75.14 379.53 25.79 4.41 0.30 
Body mass index (kg/m2) 24.44 3.89 21.86 6.47 0.30 
Waist/ hip ratio 0.88 0.08 0.88 0.07 0.90 
Waist/ height ratio 0.51 0.07 0.48 0.10 0.40 
Albumin/ creatinine ratio (µg/ g 
creatinine) 
71.94 73.49 11.27 4.28 0.0001 
Total cholesterol (mg/dl) 194.86 63.65 159.94 22.20 0.0001 
Triglyceride (mg/dl) 106.59 53.12 88.21 30.37 0.03 
HDL-c(mg/dl) 49.31 16.35 48.78 10.01 0.40 
LDL-c (mg/dl_) 116.49 39.10 100.74 28.60 0.03 
OXLDL(mg/dl) 4.33 1.42 2.66 1.37 0.0001 
Copeptin (Pg/ml) 9.43 1.70 4.38 1.28 0.0001 
Carotid intimal medial thickness 
(mm) 
0.52 0.06 0.41 0.03 0.0001 
Aortic intimal medial thickness (mm) 0.72 0.11 0.46 0.04 0.0001 
Resistivity index 0.67 0.04 0.65 0.05 0.30 
HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; OxLDL: 
Oxidized low-density lipoprotein. 
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Copeptin was significantly higher in diabetic 
patients with positive aIMT and cIMT (Table 2). 
Table 2: Comparison between copeptin concerning aortic 
intimal medial thickness and carotid intimal medial thickness 
in type 1 diabetic patients 
Copeptin (Pg/ml) 
Negative aIMT Positive aIMT 
P-value 
Mean SD Mean SD 
6.65 0.49 9.54 1.65 0.02 
Negative 
cIMT 
Positive 
cIMT 
Negative 
cIMT 
Positive 
cIMT 
0.0001 
Mean SD Mean SD 
8.08 0.98 8.08 0.98 
aIMT: Aortic intimal medial thickness; cIMT: carotid intimal medial thickness. 
 
Copeptin had a positive correlation with age 
of diabetic patients, cIMT and aIMT (Table 3). 
Table 3: Correlation between copeptin with demographics, 
laboratory data, anthropometric data and image study of 
diabetic patients 
Variables 
Copeptin 
r P-value 
Demographic data 
  
Age of diabetic patients (yrs) 0.32 0.01 
Duration of diabetes (yrs) 0.11 0.39 
Onset of disease (yrs) 0.23 0.07 
Insulin dose (u/kg) 0.04 0.75 
Blood pressure (mmHg) 
  
Systolic blood pressure (mmHg) 0.02 0.85 
Diastolic blood pressure (mmHg) 0.06 0.65 
Anthropometric data 
  
Midarm circumference (mm) 0.18 0.17 
Body mass index (kg/m2) 0.12 0.37 
Waist/ hip ratio 0.13 0.32 
Waist/height ratio 0.17 0.18 
Laboratory data 
  
HbA1c (%) 0.02 0.87 
Albumin/ creatinine ratio (µg/ g 
creatinine) 
0.05 0.78 
Total cholesterol (mg/dl) 0.10 0.47 
Triglyceride (mg/dl) 0.14 0.30 
HDL-c (mg/dl) 0.08 0.57 
LDL-c (mg/dl) 0.03 0.82 
OxLDL (mg/dl) 0.06 0.62 
Image study 
  
carotid intimal medial 
thickness(mm) 
0.40 0.0001 
Aortic intimal medial thickness 
(mm) 
0.86 0.0001 
Resistivity index 0.11 0.40 
HbA1c: Glycosylated haemoglobin; HDL-c: High-density lipoprotein cholesterol; LDL-c: 
Low-density lipoprotein cholesterol; OxLDL: Oxidized low-density lipoprotein. 
 
Stepwise multiple regression analysis of 
copeptin concerning demographic, anthropometric 
data, laboratory data and image study in type 1 
diabetic patients were shown in Table 4.  
Table 4: Stepwise multiple regression analysis of copeptin 
about demographics, anthropometric data, laboratory data and 
image study in type 1 diabetic patients 
 
Unstandardized coefficent Standardized coefficent 
P-value 
B SE Beta t 
(Constant) 2.14 1.59 
 
1.35 0.19 
aIMT (mm) 10.23 2.06 0.76 4.97 0.0001 
Dependent variables are copeptin; aIMT: aortic intimal medial thickness. 
 
ROC curve of copeptin for detection of 
atherosclerosis in relation to carotid intimal medial 
thickness and aortic intimal medial thickness in type 1 
diabetic (Table 5). 
 
 
Table 5: ROC curve of copeptin for detection of atherosclerosis 
concerning carotid intimal medial thickness and aortic intimal 
medial thickness in type 1 diabetic patients 
Variables Cut off AUC SE 95%C.I Sensitivity Specificity 
cIMT > 9 0.8 0.07 0.7 – 0.9 60.7 100 
aIMT > 7 1.0 0.02 0.9 – 1.0 95.2 100 
ROC: Receiver operating characteristic curve; aIMT: Aortic intimal medial thickness; cIMT: 
Carotid intimal medial thickness; AUC: Area under the curve; SE: Standard error; CI: 
Confidence interval. 
 
 
Discussion 
 
In our study, adolescent type 1 diabetic 
patients had higher HbA1c, microalbuminuria, 
dyslipidemia and higher aIMT and cIMT. aIMT was 
found to be higher than cIMT in diabetic patients. This 
result is comparable with previous studies [15], [16]. 
Järvisalo et al., [17] revealed that young type 1 
diabetic patients had an increased incidence of 
subclinical atherosclerosis. McGill et al., [12] found 
that intima of the abdominal aorta is affected before 
intima of the carotid artery and aIMT is an early 
diagnosis of preclinical atherosclerosis in children 
[18]. 
In the current study, copeptin was higher in 
adolescent type 1 diabetics and patients with higher 
cIMT and aIMT. Stepwise multiple regression analysis 
revealed that copeptin had a significant correlation 
with aIMT. Our results are comparable with the result 
of [19]. Copeptin had a strong relationship with 
atherosclerosis and diabetic kidney disease in adult's 
type 1 diabetic patient [19]. 
In the present study, copeptin had no 
significant correlation with albumin/creatinine ratio. As 
Copeptin and AVP are secreted from 
neurohypophysis, their level increase in many medical 
conditions in type 2 diabetic patients such as acute 
myocardial infarction [20], cardiovascular mortality [3] 
and diabetic kidney disease. 
Vasopressin may lead to an increase in blood 
pressure (systemic and glomerular) as it leads to an 
increase in vasoconstriction of blood vessels, 
enhancing gluconeogenesis, glucagon release and 
leads to fat accumulation. Vasopressin aggravates 
kidney disease in animals and leads to an increase in 
proteinuria in humans [2]. 
Bjornstad et al., [19], revealed that copeptin is 
high in adult type 1 diabetic patients and is related to 
albuminuria, impaired glomerular filtration rate (GFR) 
and increase in coronary calcium calcification. 
Increase copeptin level is associated with cardiorenal 
complications irrespective to the control of blood 
glucose, lipid profile and blood pressure. Also, Schiel 
et al., [21] reported that copeptin might be considered 
as a marker of renal function in children and 
adolescents with type 1 diabetes mellitus. Moreover, 
the concentration of copeptin may also be related to 
stress, behavioural and lifestyle factors as well as 
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inflammatory activity and the lipid profile. 
In the current study, ROC curve of copeptin 
showed that the cut off level of copeptin for detection 
of aIMT was > 7 with specificity and sensitivity 100% 
and 95.2% respectively and for cIMT cut off was > 9 
and specificity and sensitivity 100% and 60.7%. 
Copeptin has better sensitivity and specificity with 
aIMT, which is early affected before cIMT and can be 
used as early detection of atherosclerosis. 
In conclusion, copeptin is high in adolescent 
type 1 diabetic patients irrespective of control of blood 
glucose, dyslipidemia and hypertension. It can be 
used for early detection of atherosclerosis. Copeptin 
has no relation to diabetic nephropathy. AVP 
(Vapans) can be given to adolescent type 1 diabetic 
patients with cardiorenal complications. A follow-up 
study and increase number of patients is 
recommended to detect if copeptin is a cause of 
occurrence of diabetic atherosclerosis. 
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